Search
Minnesota Paid Clinical Trials
A listing of 2108 clinical trials in Minnesota actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 12 of 2108
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Location
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Minnesota is currently home to 2108 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Minneapolis, Rochester, Saint Paul and Duluth. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Clinical Study
Recruiting
We are evaluating an investigational treatment to see if it may help people dealing with chronic cough.
Eligible participants will receive study-related medical care at no cost. You may be compensated for study-related travel and time. Health insurance is not required.
Eligible participants will receive study-related medical care at no cost. You may be compensated for study-related travel and time. Health insurance is not required.
Conditions:
Cough
Chronic Cough
Asthma
Allergic Asthma
Sinusitis
Featured Trial
Transcranial Magnetic Stimulation (TMS) for Obsessive Compulsive Disorder (OCD)
Recruiting
Transcranial magnetic stimulation (TMS) is an FDA-approved, non-invasive form of brain stimulation for OCD. TMS has been shown to be an effective form of treatment in individuals with OCD. By using a form of TMS termed theta-burst stimulation (TBS), we hope that this will result in a more effective treatment by producing faster symptom reduction. We are trialing a novel form of accelerated TMS, where we will deliver ten 10-minute sessions per day, for 5 days. This study will compare the efficacy of TMS for OCD at two distinct brain regions. Participants will be randomized into one of two study groups, and receive stimulation at either the DMPFC or R-OFC. Both regions have been linked to OCD by research. Patients that don't respond to their study region will have the option to receive stimulation at the other region.
Conditions:
Obsessive-Compulsive Disorder
Obsessive Compulsive Disorder
Obsessive Compulsive Disorder (OCD)
Obsessive-Compulsive Disorder (OCD)
Obsessive-compulsive Disorders and Symptoms
Featured Trial
Depression Clinical Studies
Recruiting
Need new medication for depression? Help us study an investigational medication to potentially help people with MDD. Qualified participants may receive reasonable compensation for trial-required travel expenses.
Conditions:
Major Depressive Disorder
Major Depression
Major Depressive Episode
Major Depressive Disorder (MDD)
Major Depressive Disorder
Featured Trial
Bipolar Disorder Study (Medicare Required)
Recruiting
Non-drug Bipolar Depression study for adults with Medicare. If you have Bipolar Disorder, are over the age of 18, and are currently depressed, you may be eligible to take part in this study. If you have tried at least four treatments and not found them helpful, you are a good candidate for this study. All study-related care will be provided at no cost to you.
Conditions:
Bipolar Disorder
Bipolar Depression
Bipolar I Disorder
Depression
Bipolar
Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders
Recruiting
The researchers are testing a medication named ravulizumab for the treatment of severe preeclampsia and Hemolysis, Elevated Liver enzymes, Low Platelets (HELLP) syndrome.
Gender:
Female
Ages:
Between 18 years and 50 years
Trial Updated:
06/21/2024
Locations: Mayo Clinic Minnesota, Rochester, Minnesota
Conditions: Preeclampsia
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
Recruiting
The purpose of this study is to evaluate long-term safety and efficacy of povorcitinib in participants with moderate to severe hidradenitis suppurativa who completed the 54 weeks of study treatment within the originating parent Phase 3 studies (INCB 54707-301 [NCT05620823] or INCB 54707-302 [NCT05620836]).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: Investigative Site US212, Minneapolis, Minnesota
Conditions: Hidradenitis Suppurativa (HS)
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Recruiting
The primary objective of the study is to compare sacituzumab tirumotecan combined with pembrolizumab to pembrolizumab alone with respect to overall survival (OS). The primary hypothesis is that the combination of sacituzumab tirumotecan and pembrolizumab is superior to pembrolizumab alone with respect to OS.
All participants who have completed the first course of pembrolizumab may be eligible for up to an additional 9 cycles of pembrolizumab monotherapy if there is blinded independent central r... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: Allina Health Cancer Institute - Abbott Northwestern Hospital ( Site 0115), Minneapolis, Minnesota
Conditions: Non-small Cell Lung Cancer (NSCLC)
Phase 2B Safety and Efficacy Study of VGT-309 in Subjects With Cancer in the Lung.
Recruiting
This is a Phase 2, multi-center, open-label study to evaluate the safety and efficacy of VGT-309, a tumor-targeted, activatable fluorescent imaging agent, in subjects undergoing surgery for proven or suspected cancer in the lung. Approximately 100 subjects will be enrolled to ensure at least 86 subjects are evaluable with the option to expand enrollment by protocol amendment if deemed necessary by the DSC to meet primary and/or secondary objectives.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Lung Cancer, Lung Metastases
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
Recruiting
The purpose of this randomized, double-blind, placebo-controlled, parallel group study is to determine the efficacy of frexalimab in delaying the disability progression and the safety up to approximately 51 months administration of study intervention compared to placebo in male and female participants with nrSPMS (aged 18 to 60 years at the time of enrollment). People diagnosed with nrSPMS are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion crite... Read More
Gender:
All
Ages:
Between 18 years and 60 years
Trial Updated:
06/21/2024
Locations: Minnesota Center for Multiple Sclerosis Site Number : 8400073, Plymouth, Minnesota
Conditions: Multiple Sclerosis
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Recruiting
The purpose of this study is to assess the efficacy and safety of opevesostat plus hormone replacement therapy (HRT) compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) previously treated with one next-generation hormonal agent (NHA). The primary study hypotheses are that opevesostat is superior to alternative abiraterone acetate or enzalutamide with respect to radiographic progression free survival (rPFS) per P... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: HealthPartners Cancer Research Center-HealthPartners Frauenshuh Cancer Center ( Site 0072), Saint Louis Park, Minnesota
Conditions: Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
Recruiting
This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall survival (OS) and to radiographic progression-free survival (rPFS) per Prostate Cancer Working Group (PCWG) Modified Response Evaluation Criteria In Solid Tumors (RECIST 1.1) as assessed by blinded independent central review (BICR) in participants with mCRPC previously treate... Read More
Gender:
All
Ages:
All
Trial Updated:
06/21/2024
Locations: Metro-Minnesota Community Clinical Oncology ( Site 0014), Saint Louis Park, Minnesota
Conditions: Prostate Cancer Metastatic
Chemotherapy Combined With Immunotherapy vs Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Recruiting
This phase III trial compares the effect of adding chemotherapy to immunotherapy (pembrolizumab) versus immunotherapy alone in treating patients with stage IIIB-IV lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividin... Read More
Gender:
All
Ages:
70 years and above
Trial Updated:
06/21/2024
Locations: Sanford Joe Lueken Cancer Center, Bemidji, Minnesota
Conditions: Advanced Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
An Evaluation of Patient Reported Outcomes and Clinical Outcomes
Recruiting
This extension study is being conducted to assess the following objectives through 12 months post-cardiac surgery:
Patient reported outcomes (PRO), using the EQ-5D questionnaire
Clinical outcomes
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: Research Site, Rochester, Minnesota
Conditions: Post-Operative Complications in Cardiac Surgery
Effect of RBT-1 on Reducing the Risk of Post-Operative Complications in Subjects Undergoing Cardiac Surgery
Recruiting
The purpose of this study is to evaluate the effect of RBT-1 on reducing the risk of post-operative complications in subjects undergoing cardiac surgery on cardiopulmonary bypass (CPB). A sub-study will also be conducted to evaluate the pharmacokinetic (PK) profile of a single administration of RBT-1 by means of a popPK approach in subjects scheduled to undergo cardiac surgery.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: Research Site, Rochester, Minnesota
Conditions: Post-Operative Complications in Cardiac Surgery
Strategy for Improving Stroke Treatment Response
Recruiting
SISTER is a Phase-II, prospective, randomized, placebo-controlled, blinded, dose finding trial that aims to determine the safety and preliminary efficacy of TS23, a monoclonal antibody against the alpha-2 antiplasmin (a2-AP), in acute ischemic stroke.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: M Health Fairview Ridges Hospital, Burnsville, Minnesota
Conditions: Ischemic Stroke
Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma
Recruiting
This study is a Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered, Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: University of Minnesota- Masonic Cancer Center, M Health Fairview, Minneapolis, Minnesota
Conditions: Cholangiocarcinoma